These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23200915)

  • 1. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer.
    Ivan C; Hu W; Bottsford-Miller J; Zand B; Dalton HJ; Liu T; Huang J; Nick AM; Lopez-Berestein G; Coleman RL; Baggerly KA; Sood AK
    Gynecol Oncol; 2013 Mar; 128(3):506-11. PubMed ID: 23200915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    Fang L; Wang H; Li P
    Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis.
    Agustriawan D; Huang CH; Sheu JJ; Lee SC; Tsai JJP; Kurubanjerdjit N; Ng KL
    Comput Biol Chem; 2016 Dec; 65():154-164. PubMed ID: 27746113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma.
    Jung SG; Kwon YD; Song JA; Back MJ; Lee SY; Lee C; Hwang YY; An HJ
    Cancer Sci; 2010 Sep; 101(9):1977-83. PubMed ID: 20624166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis.
    Liu F; Zhang G; Lv S; Wen X; Liu P
    J Cell Biochem; 2019 Aug; 120(8):12618-12627. PubMed ID: 30834603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
    Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
    BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
    Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
    Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes virus microRNA expression and significance in serous ovarian cancer.
    Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
    PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
    Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
    Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synchronous profiling of mRNA N6-methyladenosine modifications and mRNA expression in high-grade serous ovarian cancer: a pilot study.
    Yang L; Liu J; Jin Y; Xing J; Zhang J; Chen X; Yu A
    Sci Rep; 2024 May; 14(1):10427. PubMed ID: 38714753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
    Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R
    Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
    Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
    Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL-R3-related apoptosis: epigenetic and expression analyses in women with ovarian neoplasia.
    Braga Lda C; Alvares da Silva Ramos AP; Traiman P; Silva LM; Lopes da Silva-Filho A
    Gynecol Oncol; 2012 Aug; 126(2):268-73. PubMed ID: 22555108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.
    Creighton CJ; Fountain MD; Yu Z; Nagaraja AK; Zhu H; Khan M; Olokpa E; Zariff A; Gunaratne PH; Matzuk MM; Anderson ML
    Cancer Res; 2010 Mar; 70(5):1906-15. PubMed ID: 20179198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct prognostic values of four-Notch-receptor mRNA expression in ovarian cancer.
    Zhou X; Teng L; Wang M
    Tumour Biol; 2016 May; 37(5):6979-85. PubMed ID: 26662955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
    Lee CH; Subramanian S; Beck AH; Espinosa I; Senz J; Zhu SX; Huntsman D; van de Rijn M; Gilks CB
    PLoS One; 2009 Oct; 4(10):e7314. PubMed ID: 19798417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor survival with wild-type TP53 ovarian cancer?
    Wong KK; Izaguirre DI; Kwan SY; King ER; Deavers MT; Sood AK; Mok SC; Gershenson DM
    Gynecol Oncol; 2013 Sep; 130(3):565-9. PubMed ID: 23800698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.
    Hedditch EL; Gao B; Russell AJ; Lu Y; Emmanuel C; Beesley J; Johnatty SE; Chen X; Harnett P; George J; ; Williams RT; Flemming C; Lambrechts D; Despierre E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching P; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Nakanishi T; Yatabe Y; Pejovic T; Bean Y; Heitz F; Harter P; du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan J; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut J; Iversen E; Weber RP; Berchuck A; Goode E; Bowtell DD; Chenevix-Trench G; deFazio A; Norris MD; MacGregor S; Haber M; Henderson MJ
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.
    Dwivedi SK; Mustafi SB; Mangala LS; Jiang D; Pradeep S; Rodriguez-Aguayo C; Ling H; Ivan C; Mukherjee P; Calin GA; Lopez-Berestein G; Sood AK; Bhattacharya R
    Oncotarget; 2016 Mar; 7(12):15093-104. PubMed ID: 26918603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.